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Background: The histopathologic pattern is currently the most important prognostic marker for
idiopathic interstitial pneumonia (IIP). However, more highly sensitivemarkers are now required.
Heat shockprotein (HSP)47,acollagen-specificmolecular chaperone, is involved in theprocessing
and/or secretion of procollagens, and it has been demonstrated that HSP47 expression is signifi-
cantly higher in the lung specimens of idiopathic UIP than in UIP associatedwith collagen vascular
diseases (CVD). However, its expression in nonspecific interstitial pneumonia (NSIP), the other
common pathological pattern of IIP, has not been well investigated. Therefore, the association
between lung fibroblast HSP47 expression and prognosis in fibrotic NSIP was evaluated.
Methods: Surgical lungbiopsy specimensof63patients [idiopathicfibroticNSIPZ 19,fibroticNSIP
associated with CVDZ 9, idiopathic UIPZ 26, and UIP associated with CVDZ 9] were reviewed,
anda score for lungfibroblastHSP47expressionwasassigned.Thesepatients’ clinical featuresand
survival were also analyzed.
Results: There was no significant difference in HSP47 expression between idiopathic fibrotic NSIP
and fibrotic NSIP associated with CVD. The idiopathic fibrotic NSIP patients with higher HSP47r lavage fluid; CVD, collagen vascular disease; DM, dermatomyositis; I-fNSIP, idiopathic fibrotic
P, heat shock protein; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; MCTD,
, Sjo¨gren syndrome; SSc, systemic sclerosis; I-UIP, idiopathic usual interstitial pneumonia.
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896 M. Amenomori et al.expression levels in their lung specimens had a poorer prognosis than patients with lower HSP47
expression levels.
Conclusions: The present results suggest that lung fibroblast HSP47 expression may be a useful
new prognostic marker for idiopathic fibrotic nonspecific interstitial pneumonia.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Idiopathic interstitial pneumonia (IIP) is currently classified
into seven clinico-radiologic-pathologic entities, which
differ not only in pathology but also in their clinical
features.1 Of these, the majority of IIP cases are nonspe-
cific interstitial pneumonia (NSIP) and usual interstitial
pneumonia (UIP). Idiopathic NSIP (I-NSIP) has been repor-
ted to have a more favorable prognosis and a better
response to steroids than idiopathic pulmonary fibrosis
(idiopathic UIP; I-UIP),2e5 suggesting that the pathogenesis
of I-NSIP is different from that of I-UIP. In addition,
whether I-NSIP is a distinct entity remains controversial
because the reported survival rates of I-NSIP patients are
variable,2,4e8 and NSIP has a close relationship with
collagen vascular disease (CVD).7,9 Though the most
common pathological patterns in interstitial pneumonia
associated with CVD (CVD-IP) are also NSIP and UIP,
patients with CVD-IP have been reported to have a better
prognosis than patients with IIP.4, 10 In this context, Flah-
erty et al.10 reported that patients with CVD-associated
UIP (CVD-UIP) have fewer fibroblastic foci in the lung than
those with I-UIP. However, the phenotypic difference in
lung cells between these diseases and its association with
the prognosis are poorly understood.
Heat shock protein 47 (HSP47), localized in the endo-
plasmic reticulum, is involved in the synthesis/assembly of
various collagens as a collagen-specific molecular chap-
erone. HSP47 expression is regulated in parallel with
collagen expression, and HSP47 overexpression leads to
production of excess extracellular matrix, which then
results in various fibrotic diseases.11e13 We have previously
reported that HSP47 was strongly expressed in the lung cells
of patients with I-UIP,14 and that the HSP47 expression level
in lung cells was significantly higher in I-UIP than in CVD-
UIP.13 These findings suggest that I-UIP and CVD-UIP have
different fibrotic pathways, and that HSP47 expression may
be a good predictor of prognosis in patients with fibrotic IP.
Therefore, in this study, the expression of HSP47 in lung
fibroblasts was examined in fibrotic IP, including fibrotic I-
NSIP (I-fNSIP), fibrotic CVD-NSIP (CVD-fNSIP), I-UIP and CVD-
UIP, to evaluate the usefulness of HSP47 as a prognostic
marker.Materials and methods
Study populations
The subjects of this study were patients who attended the
Nagasaki University Hospital between 1991 and 2007. The
study protocol was approved by the human ethics review
committees of Nagasaki University School of Medicine, andwritten, informed consent was obtained from each patient.
The subjects included 63 patients (45 with IIP and 18 with
CVD-IP) diagnosed based on surgical lung biopsy as fNSIP
pattern (19 with I-fNSIP, 9 with CVD-fNSIP) or UIP pattern
(26 with I-UIP, and 9 with CVD-UIP) according to the
consensus criteria of the American Thoracic Society/Euro-
pean Respiratory Society.1 None of the patients were
pathologically diagnosed as having cellular-NSIP. The asso-
ciated diagnoses in the CVD-fNSIP patients were rheuma-
toid arthritis (nZ 1), mixed connective tissue disease
(MCTD; nZ 1), systemic sclerosis (SSc; nZ 2), dermato-
myositis (DM; nZ 4), and DMþ Sjo¨gren syndrome (SjS;
nZ 1). The associated diagnoses in the CVD-UIP patients
were MCTD (nZ 1), SjS (nZ 3), SSc (nZ 3), DMþ SjS
(nZ 1), and SScþ SjS (nZ 1). The mean follow-up period
after the surgical lung biopsy was 69.6 5.8 (range: 1e195)
months. None of the patients had received steroids or other
immunosuppressive therapies when the surgical lung biopsy
was performed. Patients’ data before surgical lung biopsy,
including age, smoking history, results of pulmonary func-
tion tests, arterial blood gas analysis, and bronchoalveolar
lavage fluid (BALF) findings, were collected from the
hospital medical records (Tables 1 and 2). Control lung
tissues were obtained from normal areas of surgically
resected lung specimens from patients with lung cancer (4
men and 6 women; median age, 59.7 years; mean SEM
age, 67 2 years).
Antibodies
The primary antibodies used for the immunohistochemical
study included anti-HSP47 (Biotechnologies Corp., Victoria,
Canada). Negative control studies were performed using
irrelevant immunoglobulin G with the same subclass as the
first antibodies instead of the primary antibodies.
Immunohistochemistry
Immunohistochemistry was performed with the conventional
avidin-biotin-peroxidase histochemical technique using the
Vecstain Elite ABC Kit (Vector Laboratories, Burlingame, CA,
USA). Briefly, sequential paraffin sections (4 mm thick) were
deparaffinized with toluene and rinsed thoroughly with
ethanol. The sections were then soaked in 0.3% H2O2 with
absolute methanol for 20 min at room temperature to inac-
tivate the endogenous peroxidase activity. They were incu-
bated with blocking serum for 30 min, and then covered with
primary antibodies at 4 C overnight. After washing in phos-
phate-buffered saline, the sections were processed further
using the kits according to the instructions provided by
the manufacturer, and then developed with 3,30-dia-
minobenzidine and H2O2, followed by Mayer’s hematoxylin
staining method.
Table 1 Clinical characteristics of fibrotic NSIP and UIP patients.
Idiopathic-fNSIP (nZ 19) CVD-fNSIP (nZ 9) Idiopathic-UIP (nZ 26) CVD-UIP (nZ 9) p Value
Age at SLB (y) 58 2.7 55.7 3.3 61.2 1.8 51.9 3.7 0.1295
Sex (male/female) 8/11 2/7 20/6 3/6 0.0086
Smoking (N/Ex/C/U) 11/5/2/1 4/2/0/3 9/10/7 5/4/0 0.3197
Concomitant CVD RA 1 MCTD 1
MCTD 1 SjS 3
SSc 2 SSc 3
DM 4 DMþ SjS 1
DMþ SjS 1 SScþ SjS 1
CVD, collagen vascular disease; DM, dermatomyositis; MCTD, mixed connective tissue disease; RA, rheumatoid arthritis; SjS, Sjo¨gren
syndrome; SLB, surgical lung biopsy; SSc, systemic sclerosis; N/Ex/C/U, never/ex-/current/unknown.
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The staining intensity and distribution of HSP47 in fibro-
blasts in active fibrotic areas (fibroblastic foci in UIP cases;
alveolar septal interstitium expanded by fibrosis and intra-
alveolar organizing fibrosis in fNSIP cases) were scored
semi-quantitatively using a grading system of 0 to 3
(0Z negative; 1Zweak; 2Zmoderate; 3Z strong). The
immunohistochemical score for each patient was calcu-
lated by averaging the score of each lobe. Histological
sectionswere assessed independently, twice by each of two
observers, and then analyzed statistically. Analysis ofTable 2 Clinical characteristics of fibrotic NSIP and UIP patient
Idiopathic-fNSIP (nZ 19) CVD-
Pulmonary function tests
VC (L) 2.22 0.19 2.19
%VC (%) 74.7 4.3 76.7
FEV1.0 (L) 1.79 0.15 1.7
FEV1.0 (%) 79.2 3.6 80.7
%DLCO (%) 61.2 5.0 53.2
%VC/%DLCO 1.37 0.10 1.53
Arterial blood gas
PaCO2 (Torr) 81.3 1.6 81
PaO2 (Torr) 41.3 0.9 39.7
PaO2/FiO2 ratio 381.3 9.6 385.5
Laboratory data
KL-6 (U/ml) 1528 268 859
SP-D (ng/ml) 299.8 44.9 90.3
SP-A (ng/ml) 81.8 18.5 62.9
LDH (IU/ml) 227.9 19.7 327.5
CRP (mg/dl) 0.61 0.22 1.74
BALF findings
Cell recovery (105/ml) 3.6 0.4 4.6
Macrophages (%) 49.5 4.9* 52.1
Lymphocytes (%) 39.4 3.6* 30.2
Neutrophils (%) 3.6 1 14.6
Eosinophils (%) 3.1 0.9 2.8
CD4/CD8 1.92 1.24 0.96
Values are expressed as mean SE.
BALF, bronchoalveolar lavage fluid; CVD, collagen vascular disease-as
*p< 0.05 compared with Idiopathic-UIP; **p< 0.05 compared with Idiinterobserver and intraobserver variability showed that the
results were reproducible.
Statistical analysis
All values are described as mean standard error. Differ-
ences in categorical data between two groups were
assessed by Fisher’s exact probability test for data with two
categories and by chi-square test for data with three or
more categories. Differences in continuous data between
two groups were assessed using the Wilcoxon rank-sum test,
and differences in continuous data among three groupss.
fNSIP (nZ 9) Idiopathic-UIP (nZ 26) CVD-UIP (nZ 9)
 0.22 2.51 0.13 2 48 0.36
 6.3 80 80.6 3.3 84.2 9.1
 0.17 2.02 0.1 2.05 0.32
 4.9 82.1 1.3 89.5 5
 4.5 55.6 3.2 47.3 4.6**
 0.12 1.53 0.1 1.87 0.3**
 2.5 83.1 2.4 83.3 6.1
 1.2 41.2 1.1 47.2 4.7*
 11.7 395.7 11.6 396.5 29.2
 152 1477 226 1041 169
 11.6* 257.3 30.4 225.3 55.9
 11.6 108.1 16.9 97.3 15.1
 56.1 309.3 26.7 403.3 75.1**
 0.61 0.92 0.43 0.54 0.3
 1.1 4.3 0.4 2.5 0.2*
 7.2* 71.3 3.9** 72.3 4.9**
 7.6* 15.4 3 20.3 4*,**
 6** 8.3 2.4 5.5 1.5
 1.1 4.9 1.3 2.4 1
 0.32 1.51 0.36 1.60 0.63
sociated.
opathic-fNSIP.
Figure 1 Comparison of the survival curves of all subject
groups.
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multivariate Cox regression analysis was used to examine
the relationships between the presence/absence of idio-
pathic UIP and CVD-UIP and other variables. The overall
survival experience for each group was estimated using
Kaplan-Meier curves. The log-rank test was used to
compare survival between two groups. Statistical signifi-
cance was defined by a p value of less than 0.05. All dataFigure 2 Immunohistochemical staining for HSP47 of surgical lun
NSIP. Fibroblast HSP47 score: aZ 0 (negative), bZ 1 (weak), cZwere analyzed using statistical software (Stat ViewJ-5.0,
SAS Institute, Cary, NC, USA).Results
Patient characteristics and survival
The I-fNSIP and CVD-fNSIP groups were both female-domi-
nant and in their mid-fifties (Table 1). The percentage of
neutrophils in BALF was slightly greater in CVD-fNSIP than in
I-fNSIP. Fig. 1 shows the comparison of the survival curves of
the I-fNSIP, CVD-fNSIP, I-UIP, and CVD-UIP groups. The 5-year
survival rates were: 78.2% in the I-fNSIP group; 77.8% in the
CVD-fNSIP group; 51% in the I-UIP group; and 100% in the CVD-
UIP group. Using the log-rank test, no significant difference
in survival was found between the I-fNSIP and CVD-fNSIP
groups (pZ 0.903); the I-UIP group had the worst prognosis,
which was significantly different from that of the CVD-UIP
group (pZ 0.015). The age of the patients was significantly
different between the idiopathic UIP and CVD-UIP groups
(pZ 0.0255). After accounting for the age difference using
multivariate Cox regression analysis, the prognoses of the I-
UIP and CVD-UIP subgroups were still different, though the
difference was not significantZ 0.07). There was no asso-
ciation between survival and clinical features such as serum
markers, results of pulmonary function tests, and BALF
findings (data not shown).g biopsy specimens taken from patients with idiopathic fibrotic
2 (moderate), dZ 3 (strong). Scale barZ 500 mm.
Figure 3 Box-and-whisker plots of the HSP47 scores in lung
fibroblasts in patients with idiopathic-fNSIP, CVD-fNSIP, idio-
pathic-UIP, and CVD-UIP. *p< 0.01, compared with control.
The boxes represent the 25th to 75th percentiles, the solid
lines within the boxes show the median values, the whiskers
are the 10th and 90th percentiles. CVD, collagen vascular
disease; HSP47, heat shock protein 47; fNSIP, fibrotic nonspe-
cific interstitial pneumonia; UIP, usual interstitial pneumonia.
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association with clinical findings and survival
Representative examples of immunohistochemical staining
for HSP47 in patients with I-fNSIP are shown in Fig. 2. In
fNSIP cases, unlike fibroblastic foci in UIP cases, lesions
with active fibroblast proliferation were analyzed. The
HSP47 scores in lung fibroblasts were evaluated in all
patients and controls (Fig. 2). A negative control study
using nonspecific immunoglobulin-G revealed no positive
cells (data not shown).
HSP47 expression was significantly higher in all patient
groups than in controls (vs. I-fNSIP, pZ 0.0001; vs. CVD-
fNSIP, 0.0017; vs. I-UIP, p< 0.0001; vs. CVD-UIP,
pZ 0.0065) (Fig. 3). Furthermore, the I-UIP group had
a significantly higher expression of HSP47 than the CVD-UIP
group (pZ 0.0395). No significant difference was found
between the I-fNSIP and CVD-fNSIP groups (pZ 0.335). TheFigure 4 The survival curves of the idiopathicefibrotic NSIP (A) a
on the average fibroblast HSP47 score (1.19 and 1.36, respectivelyassociations between the HSP47 score and clinical features
and laboratory data, including the pulmonary function test,
PaO2/FiO2 ratio and BALF findings, were also evaluated, but
no associations were identified (data not shown). Fig. 4
shows the survival curves of the I-fNSIP cases (A) and the I-
UIP (B) groups, divided into two subgroups based on the
average fibroblast HSP47 scores (1.19 and 1.36, respec-
tively). In the I-fNSIP group, cases with HSP47 scores higher
than the average value appeared to have a worse prognosis
than those with HSP47 scores lower than the average value,
though the p value was not calculable. In contrast, in the I-
UIP group, there was no significant association between the
HSP47 score and prognosis (pZ 0.2632). In the CVD-fNSIP
and CVD-UIP groups, there was no significant association
between the HSP47 score and prognosis (data not shown).
Discussion
The histopathologic pattern of UIP is well-characterized,
with the cardinal feature being the patchy distribution of
temporally heterogeneous fibrosis, comprising areas of
established fibrosis with adjacent foci of fibroblastic
proliferation (so-called fibroblastic foci). Recent studies
have emphasized the importance of the fibroblastic focus
as a manifestation of ongoing lung injury in patients with
established fibrosis.15e20 A number of investigators have
stressed the prognostic value of quantifying fibroblastic foci
in patients with idiopathic interstitial pneumonia.19,20
Furthermore, a previous study showed that patients with
CVD-UIP have fewer fibroblastic foci and better prognosis
than patients with I-UIP.10 In I-NSIP, which exhibits a more
favorable response to corticosteroids and has a better
prognosis than I-UIP,8,21e24 fibroblastic foci with dense
fibrosis are inconspicuous or absent.1 Thus, fibroblasts are
believed to play an important role in the progression of
chronic pulmonary fibrosis. However, previous studies did
not fully elucidate the phenotypic differences in fibroblasts
among I-UIP, CVD-UIP, I-NSIP, and CVD-NSIP.
In the present study, it was confirmed that expression of
HSP47 in lung fibroblasts was higher in I-UIP patients than in
CVD-UIP patients, as previously reported.13 In this study, we
reported the new finding that there was no significant
difference in fibroblast HSP47 expression between patientsnd idiopathic-UIP (B) groups, divided into two subgroups based
).
900 M. Amenomori et al.with I-fNSIP and those with CVD-fNSIP. It is quite interesting
that our findings suggest that I-UIP and CVD-UIP have
different fibrotic pathways, while I-fNSIP and CVD-fNSIP
might have similar fibrotic processes. This is consistent with
the recent idea that I-NSIP and CVD-NSIP might be similar
pathophysiological entities. Some authors have reported
that the prognoses of I-NSIP and CVD-NSIP patients were
similar,4,25 and that it is very difficult to distinguish I-NSIP
from NSIP associated with underlying diseases.26 In the
present study, we also demonstrated that the I-fNSIP and
CVD-fNSIP groups had almost the same prognosis (5-year
survival, 77.5% and 77.8%, respectively), and their lung
fibroblast HSP47 expression was also similar. There is
a clinical condition called undifferentiated connective
tissue disease (UCTD) characterized by the presence of
signs and symptoms suggestive of a systemic autoimmune
disease without satisfying the criteria for connective tissue
diseases.27 It has been recently hypothesized that I-NSIP is
an autoimmune disease that is the lung manifestation of
UCTD,7 or that NSIP might be the first clinical presentation
of various CVDs.9 Still, a recent report stated that I-NSIP
was a distinct clinical entity with a very good prognosis.5
Thus, the ultimate goal now is to determine what NSIP is.
Jegal et al demonstrated that decreased initial forced
vital capacity and diffusing capacity of lung for carbon
monoxide, increased age, male sex, a lower resting PaO2,
and deteriorated forced vital capacity at 6 months, in
addition to the pathologic pattern of UIP, were all associated
with increased mortality among 179 fibrotic IP patients.3 In
addition to these, the present study showed that higher
fibroblast HSP47 expression was significantly associated with
poor mortality in I-fNSIP patients. As the expression and
synthesis of HSP47 closely correlateswith that of collagens in
various cell lines and tissues of fibrosis models,13,28e31 higher
HSP47 expression reflects advanced collagen synthesis and
stronger fibrotic change in the involved lung, and this might
correlate well with poor prognosis in these diseases.
However, there was no association between fibroblast
expression of HSP47 and prognosis in I-UIP patients. These
findings imply that the association between HSP47 expres-
sion and prognosis differs somewhat between I-UIP and I-
fNSIP. The NSIP pattern encompasses a broad spectrum of
histologic features with varying degrees of alveolar wall
inflammation or fibrosis.1 Of the types of IIP, the histologic
features of NSIP do not fit the histologic pattern of UIP,
organizing pneumonia, diffuse alveolar damage, desqua-
mative interstitial pneumonia, respiratory bronchiolitis-
associated interstitial lung disease, or lymphoid interstitial
pneumonia. In contrast to UIP, it is uncertain whether NSIP is
an independent clinical entity. In view of the variable
pathology, response to treatment, and prognosis, further
subclassification is warranted. The expression of HSP47
might be useful for further subclassification of NSIP.
However, this study has limitations, in that it included only
a small number of patients and was retrospective. Further-
more, the comparisons were not adjusted for other factors.
Various selection biases (patient selection, selection of
fragments in surgical lung biopsy, and selection of therapy
for each patient) affect the results in this study. Thus, well-
planned prospective studies using a large number of patients
are required to determine the role of HSP47 as a prognostic
factor in interstitial pneumonias.In conclusion, we have shown that there was no signifi-
cant difference in fibroblast HSP47 expression between
patients with I-fNSIP and those with CVD-fNSIP. We also
have shown that higher fibroblast HSP47 expression was
significantly associated with poor mortality in I-fNSIP
patients. Our findings imply that I-fNSIP and CVD-fNSIP
might have similar fibrotic processes, and that HSP47 might
be a prognostic marker for I-NSIP. Further studies involving
a large number of patients are required to determine the
prognostic and therapeutic values of HSP47 expression.
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